Telmista of N of 80 tab. 80mg/12.5mg No. 28

tablets "Telmista of N 80" are applied in arterial hypertension. Drug in the fixed dose combination (80 mg telmizartana/12.5 hydrochlorothiazide mg) is shown for use to adult patients if reception of a telmizartan as monotherapies does not provide due control of arterial blood pressure.

Structure

One tablet contains (active ingredients):

• a telmizartan - 80 mg;
• a hydrochlorothiazide - 12.5 mg.

Excipients: Megluminum, sodium hydroxide, povidone, lactoses mnogidrat, sorbite (E 420), magnesium stearate, attracts (E 421), DC (E 421), hydroxypropyl cellulose, silicon colloidal anhydrous, the sodium stearylfumarating ferrous oxide red attracts dioxide (E 172).

Contraindication

• hypersensitivity to active ingredient or to any of medicament components;
• sensitivity to other derivatives of sulfonamide (a hydrochlorothiazide - the substance derivative of sulfonamides);
• pregnancy and planning of pregnancy;
• cholestatic and biliary obstructive disturbances;
• heavy abnormal liver functions;
• heavy renal failures (clearance of creatinine <30 ml/minute);
• refractory hypopotassemia, hypercalcemia;
• feeding by a breast;
• symptomatic hyperuricemia (gout);
• children's age (up to 18 years).

Route of administration

Drug is appointed to patients at whom arterial blood pressure is insufficiently controlled at use separately of a telmizartan. Before transition to medicament treatment it is necessary to define a dose of each of components. Direct replacement of monotherapy by the fixed combinations can be considered.

once a day to patients at whom arterial blood pressure is insufficiently controlled at use of tablets of a telmizartan of 80 mg.

Should take the medicament orally once a day, washing down with liquid, irrespective of meal.

Feature of use

Drivers

During the driving and work with mechanisms needs to be considered that at antihypertensive therapy the dizziness or drowsiness can arise drug.

Information on overdose telmizartany people is limited to

. Extent of removal of a hydrochlorothiazide by a hemodialysis is unknown.

Symptoms

Most probable expected manifestations of overdose of a telmizartan is arterial hypotension and tachycardia; also bradycardia, dizziness, vomiting, increase in creatinine of blood serum and an acute renal failure were observed. The overdose by a hydrochlorothiazide is connected with decrease in electrolytes (hypopotassemia, a hypochloraemia) and dehydration owing to an excessive diuresis. The most widespread signs and symptoms of overdose are nausea and drowsiness. The hypopotassemia can lead to a spasm of muscles and/or exacerbation of cardiac arrhythmia that are connected with simultaneous use of medicaments of a foxglove or certain antiarrhytmic drugs.

Treatment

Telmizartan does not leave by means of a hemodialysis. It is necessary to carry out careful monitoring of a condition of patients. Treatment at emergence of symptoms of overdose has to be symptomatic and supporting. Therapy depends on time of reception of a tablet and weight of symptoms. The supporting actions include induction of vomiting and/or gastric lavage. At treatment of overdose there can be useful a use of activated carbon. It is necessary to carry out monitoring of level of electrolytes and creatinine. When developing arterial hypotension of the patient it is necessary to put on a back and to help using saline and volume solutions.

Side reaction which was observed often dizziness was p>

.

Storage conditions

to Store

in original packing for protection against effect of light at a temperature not above 30 °C, out of children's reach.

Expiration date - 3 years.